{"id":"placebo-respimat","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, it contains no active pharmaceutical ingredient and is used in randomized controlled trials to establish the efficacy and safety of active respiratory medications. The Respimat is a soft-mist inhaler device that delivers the formulation as a fine aerosol to the lungs, allowing for blinded comparison against active treatments in respiratory disease studies.","oneSentence":"Placebo Respimat is an inert formulation delivered via the Respimat inhaler device that serves as a control comparator in clinical trials.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:29.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in clinical trials for respiratory diseases"}]},"trialDetails":[{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT02175342","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":202},{"nctId":"NCT01152450","phase":"PHASE2","title":"A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Asthma","enrollment":94},{"nctId":"NCT04061161","phase":"PHASE4","title":"Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-19","conditions":"COPD","enrollment":37},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT05113615","phase":"PHASE4","title":"Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2021-12-13","conditions":"Asthma","enrollment":12},{"nctId":"NCT04223843","phase":"PHASE4","title":"A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-01-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":213},{"nctId":"NCT04648813","phase":"PHASE4","title":"Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2020-11-13","conditions":"Allergic Asthma","enrollment":15},{"nctId":"NCT00528996","phase":"PHASE2","title":"An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2080},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT04059094","phase":"PHASE2","title":"A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2019-09-16","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT04780984","phase":"PHASE2","title":"Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Nephron Pharmaceuticals Corporation","startDate":"2020-11-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":116},{"nctId":"NCT03358147","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-12-13","conditions":"Asthma","enrollment":1077},{"nctId":"NCT02845752","phase":"PHASE4","title":"The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-03-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":14},{"nctId":"NCT03135899","phase":"PHASE1","title":"BI 443651 Methacholine Challenge","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-18","conditions":"Asthma","enrollment":37},{"nctId":"NCT02976519","phase":"PHASE1","title":"BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-02-15","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT03673670","phase":"PHASE2","title":"Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2018-07-16","conditions":"COPD","enrollment":79},{"nctId":"NCT03118765","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2017-03-24","conditions":"Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","enrollment":155},{"nctId":"NCT02066298","phase":"PHASE3","title":"Steroids In Eosinophil Negative Asthma","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-07","conditions":"Asthma","enrollment":295},{"nctId":"NCT03425617","phase":"PHASE4","title":"Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2017-01-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT02683109","phase":"PHASE4","title":"Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":221},{"nctId":"NCT00122434","phase":"PHASE2","title":"Dose Finding Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":389},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT02085161","phase":"PHASE3","title":"To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":304},{"nctId":"NCT01525615","phase":"PHASE3","title":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":404},{"nctId":"NCT01634139","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":403},{"nctId":"NCT02622243","phase":"PHASE4","title":"Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2015-11","conditions":"Asthma","enrollment":13},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT00932646","phase":"PHASE3","title":"Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT01634152","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":401},{"nctId":"NCT02006732","phase":"PHASE3","title":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":809},{"nctId":"NCT01964352","phase":"PHASE3","title":"Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":813},{"nctId":"NCT01533935","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":291},{"nctId":"NCT01533922","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":295},{"nctId":"NCT01559116","phase":"PHASE3","title":"Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":219},{"nctId":"NCT02030535","phase":"PHASE2","title":"Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":53},{"nctId":"NCT01040403","phase":"PHASE2","title":"Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":233},{"nctId":"NCT01634113","phase":"PHASE2","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":102},{"nctId":"NCT01383499","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-08","conditions":"Asthma","enrollment":101},{"nctId":"NCT01316380","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03","conditions":"Asthma","enrollment":465},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT02273401","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Healthy","enrollment":96},{"nctId":"NCT01277523","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Asthma","enrollment":392},{"nctId":"NCT02263976","phase":"PHASE1","title":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Healthy","enrollment":101},{"nctId":"NCT02259946","phase":"PHASE1","title":"Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Healthy","enrollment":48},{"nctId":"NCT02254720","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Healthy","enrollment":71},{"nctId":"NCT02254122","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-05","conditions":"Healthy","enrollment":59},{"nctId":"NCT02236182","phase":"PHASE2","title":"Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":57},{"nctId":"NCT00776984","phase":"PHASE3","title":"Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Asthma","enrollment":453},{"nctId":"NCT01257230","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-12","conditions":"Asthma","enrollment":398},{"nctId":"NCT01694771","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1134},{"nctId":"NCT02220660","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT02221375","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Healthy","enrollment":56},{"nctId":"NCT02220673","phase":"PHASE1","title":"Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Asthma","enrollment":61},{"nctId":"NCT00772538","phase":"PHASE3","title":"Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Asthma","enrollment":459},{"nctId":"NCT01696071","phase":"PHASE2","title":"Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Asthma","enrollment":98},{"nctId":"NCT02181335","phase":"PHASE3","title":"Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-10","conditions":"Asthma","enrollment":684},{"nctId":"NCT02177344","phase":"PHASE3","title":"Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":646},{"nctId":"NCT02182479","phase":"PHASE3","title":"Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Asthma","enrollment":631},{"nctId":"NCT02173782","phase":"PHASE3","title":"Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":892},{"nctId":"NCT01040793","phase":"PHASE3","title":"Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":157},{"nctId":"NCT01040130","phase":"PHASE3","title":"Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":151},{"nctId":"NCT01340209","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT00928668","phase":"PHASE2","title":"Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01","conditions":"Asthma","enrollment":32},{"nctId":"NCT00931385","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":99},{"nctId":"NCT01040689","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":108},{"nctId":"NCT01040728","phase":"PHASE3","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT00793624","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":906},{"nctId":"NCT00796653","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":937},{"nctId":"NCT01013753","phase":"PHASE2","title":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Asthma","enrollment":198},{"nctId":"NCT00824382","phase":"PHASE2","title":"Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":328},{"nctId":"NCT00467740","phase":"PHASE2","title":"Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-05","conditions":"Asthma","enrollment":296},{"nctId":"NCT00782509","phase":"PHASE3","title":"12 / 48 wk Pivotal PFT vs PBO in COPD II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":644},{"nctId":"NCT00452400","phase":"PHASE2","title":"Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-03","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":409},{"nctId":"NCT02177253","phase":"PHASE3","title":"Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1118},{"nctId":"NCT02172534","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Cystic Fibrosis","enrollment":113},{"nctId":"NCT02172144","phase":"PHASE1","title":"Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT02171780","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-02","conditions":"Healthy","enrollment":122},{"nctId":"NCT01126437","phase":"PHASE3","title":"Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17183},{"nctId":"NCT00400153","phase":"PHASE3","title":"Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1480},{"nctId":"NCT01172808","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Asthma","enrollment":1071},{"nctId":"NCT00782210","phase":"PHASE3","title":"12 / 48 Week Pivotal PFT vs PBO in COPD I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":625},{"nctId":"NCT01172821","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Asthma","enrollment":1032},{"nctId":"NCT00168831","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1007},{"nctId":"NCT00168844","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":983},{"nctId":"NCT00387088","phase":"PHASE3","title":"Tiotropium / Respimat One Year Study in COPD.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3991},{"nctId":"NCT01122680","phase":"PHASE2","title":"Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Asthma","enrollment":105},{"nctId":"NCT01222533","phase":"PHASE2","title":"Tiotropium Respimat Pharmacokinetic Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":154},{"nctId":"NCT00737100","phase":"PHASE2","title":"Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-09","conditions":"Cystic Fibrosis","enrollment":510},{"nctId":"NCT01311661","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03","conditions":"Asthma","enrollment":206},{"nctId":"NCT00350207","phase":"PHASE2","title":"Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-07","conditions":"Asthma","enrollment":388},{"nctId":"NCT01179347","phase":"PHASE3","title":"Tiotropium Bromide in Cystic Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Cystic Fibrosis","enrollment":464},{"nctId":"NCT01233284","phase":"PHASE2","title":"Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11","conditions":"Asthma","enrollment":149},{"nctId":"NCT00281567","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT00240435","phase":"PHASE3","title":"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":491},{"nctId":"NCT00239473","phase":"PHASE3","title":"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":429},{"nctId":"NCT01458886","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT00128440","phase":"PHASE2","title":"High Dose Trial in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":78},{"nctId":"NCT00365560","phase":"PHASE2","title":"An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-08","conditions":"Asthma","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(Spiriva®, Striverdi® or","Spiolto®)"],"phase":"marketed","status":"active","brandName":"Placebo Respimat","genericName":"Placebo Respimat","companyName":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","companyId":"lundquist-institute-for-biomedical-innovation-at-harbor-ucla-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo Respimat is a placebo used in clinical trials for various conditions, including Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, and Smoking, via the Respimat inhaler device. The active ingredients in Placebo Respimat are not specified, but it is a small molecule modality.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Spiolto","application_number":"Spiolto"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}